Flexion Reports Year-End 2014 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Flexion Therapeutics (FLXN) PT Raised to $34.50 at Janney Capital
March 24, 2015 6:34 AM EDTJanney Capital analyst Chiara Russo reiterated a Buy rating and lifted her price target on Flexion Therapeutics (NASDAQ: FLXN) to $34.50 (from $30.00) after the company announced 2014 year end results that were relatively in line with the firm's expectations. Russo also notes Phase... More
Flexion Therapeutics (FLXN) Reports Q4 Loss of $1.97
March 23, 2015 4:14 PM EDTFlexion Therapeutics (NASDAQ: FLXN) reported Q4 EPS of ($1.97), versus ($23.02) reported last year.
Anticipated Events in 2015
Announce the results of pivotal Phase 2b trial in the fourth quarterComplete final, pivotal Phase 3 clinical trial enrollment for FX006For earnings history and earnings-related data on Flexion Therapeutics (FLXN) click here.
... More